Evidence map›Paper›PMID 28292578›Full record

ArticleEBioMedicine2017

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

H Ross-Adams, A D Lamb, M J Dunning, S Halim, J Lindberg, C M Massie, L A Egevad, R Russell, A Ramos-Montoya, S L Vowler and 15 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

H Ross-AdamsCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Ross-AdamsH@cardiff.ac.uk.
A D LambCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK; Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK. Electronic address: Alastair.Lamb@cruk.cam.ac.uk.
M J DunningCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Mark.Dunning@cruk.cam.ac.uk.
S HalimCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Silvia.Halim@cruk.cam.ac.uk.
J LindbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: Charlie.Massie@cruk.cam.ac.uk.
C M MassieCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: johan.lindberg@ki.se.
L A EgevadDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: Lars.Egevad@ki.se.
R RussellCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Roslin.Russell@cruk.cam.ac.uk.
A Ramos-MontoyaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Antonio.Ramos-Montoya@cruk.cam.ac.uk.
S L VowlerCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Sarah.Vowler@cruk.cam.ac.uk.
N L SharmaNuffield Department of Surgical Sciences, University of Oxford, Roosevelt Drive, Oxford, UK. Electronic address: naomi.sharma@nds.ox.ac.uk.
J KayCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK. Electronic address: Jonathan.Kay@cruk.cam.ac.uk.
H WhitakerCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK. Electronic address: Hayley.Whitaker@cruk.camac.uk.
J ClarkUniversity of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. Electronic address: jeremy.clark@uea.ac.uk.
R HurstUniversity of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. Electronic address: R.Hurst1@uea.ac.uk.
V J GnanapragasamDepartment of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK; Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK. Electronic address: vjg29@cam.ac.uk.
N C ShahDepartment of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. Electronic address: nimish.shah@addenbrookes.nhs.uk.
A Y WarrenDepartment of Pathology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. Electronic address: anne.warren@addenbrookes.nhs.uk.
C S CooperUniversity of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. Electronic address: colin.cooper17@ntlworld.com.
A G LynchCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Andy.Lynch@cruk.am.ac.uk.
R StarkCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK. Electronic address: Rory.Stark@cruk.cam.ac.uk.
I G MillsCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway; Department of Molecular Oncology, Institute of Cancer Research, Oslo University Hospitals, N-0424 Oslo, Norway; Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK. Electronic address: ian.mills@ncmm.uio.no.
H GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: Henrik.Gronberg@ki.se.
D E NealCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. Electronic address: den22@medschl.cam.ac.uk.
CamCaP Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28292578
PMCPMC5680481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.